Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Sarepta Therapeutics has an accrual ratio of 0.79 for the year to September 2024. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of ...

Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Fintel reports that on November 7, 2024, Cantor Fitzgerald upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Sarepta Therapeutics Inc (SRPT) reports a robust 39% revenue growth, achieving profitability while navigating strategic ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and DocGo (DCGO – Research Report) with bullish sentiments.

Uy Ear’s rating is based on several positive developments for Sarepta Therapeutics. The company demonstrated strong financial performance in its third quarter of 2024, with revenues surpassing ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

respectively Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2024. “I am pleased to ...